Updated:
Frontage Laboratories
Frontage Laboratories runs 25 drug-development sites on three continents, compressing discovery through Phase II for startups and top-20 pharma.
Frontage Laboratories
Founded over 20 years ago and headquartered in Exton, Pennsylvania, Frontage Laboratories built its business by layering scientific services—medicinal chemistry, biology, and ADME/Tox screening—on top of a core bioanalytical laboratory. The firm now supports innovators, generic manufacturers, and consumer-health companies across the entire pre-clinical and early clinical spectrum, with a client list that ranges from venture-backed startups to the top-20 global pharmaceutical companies. Its physical footprint mirrors the biopharma supply chain: 12 sites in North America, a beachhead in Europe, and another 12 sites across China. Frontage's strategy defies the narrow-CRO label by operating as a full-spectrum contract development and manufacturing organization (CDMO) alongside its service business. The platform spans drug discovery, DMPK, safety and toxicology, bioanalytical testing for small and large molecules, central lab services, and CMC product development that supports NCE, 505(b)(2), and ANDA products through Phase III clinical-trial-material manufacturing. The company also runs a dedicated agrochemical division, providing biological, chemical, and regulatory support in a GLP-compliant facility. This breadth lets a single sponsor hand a lead candidate to Frontage and receive an IND-ready package without stitching together five different vendors. With roughly 1,700 employees worldwide and more than 200 FDA inspections completed, scale is a genuine operating asset. Recent news shows the firm is not standing still: in 2024 it announced co-CEO promotions, expanded its Canadian business, launched a new site, and acquired Nucro-Technics to add bioanalytical and CMC capacity. The executive bench has been deepened with hires in clinical services and global drug discovery, signaling ambitions to compete for larger integrated programs. Frontage's structural differentiator is the deliberate co-location of discovery, development, and manufacturing under unified quality systems. While most CROs hand off work between separate legal entities and GLP/GMP regimes, Frontage applies harmonized standards across all geographies—the same SOPs govern a bioanalytical run in Exton as a DMPK study in Shanghai. That continuity reduces the data-reconciliation risk that kills IND timelines, turning regulatory submission into a single-threaded workflow rather than a multi-party negotiation.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Exton
Corporate office
Exton, PA, United States
Additional offices
Canada · China · Europe
Sector focus
Frequently asked questions
How does Frontage integrate discovery and development services that are usually split among separate vendors?
Frontage operates unified global quality systems that apply the same SOPs to every site. A sponsor's lead candidate can move from medicinal chemistry through DMPK, safety toxicology, and Phase I clinical-trial-material manufacturing without leaving Frontage's quality envelope. The firm credits this architecture with compressing timelines and lowering the data-reconciliation risk that arises when multiple CROs hand off work at each gate.
What is Frontage's geographic split, and how does it affect client programs?
The firm maintains 25 sites: 12 in North America, 12 in China, and one in Europe. The dual US-China footprint lets sponsors run parallel discovery campaigns or GLP toxicology studies in both regions under the same quality framework. Frontage explicitly markets this as a way to reduce costs and accelerate IND filings by matching a program's stage to the appropriate geography without changing vendors.
Does Frontage operate strictly as a CRO, or does it manufacture clinical-trial materials as well?
Frontage functions as both a CRO and a CDMO. Its CMC division handles formulation development, analytical services, and clinical-trial-material manufacturing for NCE, 505(b)(2), and ANDA products through Phase III. This means a sponsor can use Frontage for everything up to and including the drug product used in first-in-human studies, rather than contracting a separate CDMO after preclinical work wraps.
Which sector outside human pharma does Frontage serve, and how is that unit structured?
Frontage runs a dedicated agrochemical division that provides biological, chemical, and regulatory support within a GLP-compliant facility. The firm frames this as a natural extension of its analytical and toxicology capabilities, applying the same quality infrastructure to crop-protection products that it uses for small-molecule drugs.
How has Frontage changed its leadership recently?
The firm announced co-CEO promotions in 2024, signaling a governance shift that likely splits operational and strategic responsibilities at the top. During the same window, it added a vice president of clinical services and new global discovery leadership, suggesting a deliberate push to integrate its clinical and preclinical arms more tightly under shared executive oversight.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: